Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine

Circulation Research

Volumn 76, Issue 1, 1995, Pages 110-119

  Salata, Joseph J ^a   Jurkiewicz, Nancy K ^a   Wallace, Audrey A ^a   Stupienski III, Raymond F ^a   Guinosso Jr , Peter J ^a   Lynch Jr , Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

delayed rectifier potassium current; early afterdepolarization; torsade de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CHLORPHENIRAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; MEPYRAMINE; POTASSIUM ION; TERFENADINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; FEMALE; GUINEA PIG; HEART DEPOLARIZATION; HEART MUSCLE CELL; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE ACTION POTENTIAL; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; TORSADE DES POINTES;

EID: 0028936268     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.res.76.1.110     Document Type: Article

References (50)

1. Jackman WN, Friday KJ, Andersen JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988; 31:115-172.
2. Stratmann HG, Kennedy HL. Torsade de pointes associated with drugs and toxins: recognition and management. Am Heart J. 1987; 113:1470-1481.
3. Zipes DP. Proarrhythmic effects of antiarrhythmic drugs. Am J Cardiol. 1987;59:26E-31E.
4. Benedict CR. The QT interval and drug-associated torsade de pointes. Drug Invest. 1993;5:69-79.
5. Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther. 1991;5:515-530.
6. Craft TM. Torsade de pointes after astemizole overdose. Br Med J (Clin Res Ed). 1986;292:660.
7. Simons FER, Kesselman MS, Giddins NG, Pelech AN, Simons KJ. Astemizole-induced torsade de pointes. Lancet. 1988;2:624.
8. Snook J, Boothman-Burrell D, Watkins J, Colin-Jones D. Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract. 1988;42:257-259.
9. Hoppu K, Tikanoja T, Tapanainen P, Remes M, Saarenpaa-Heikkila O, Kouvalainen K. Accidental astemizole overdose in young children. Lancet. 1991;338:538-540.
10. Sakemi H, VanNatta B. Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval. Am Heart J. 1993;125:1436-1438.
11. Monohan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsade de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
12. Nightingale SL. Warnings issued on non-sedating antihistamines terfenadine and astemizole. JAMA. 1992;268:705.
13. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993;269:1532-1536.
14. + channel cloned from human heart. Mol Pharmacol. 1993;44:1240-1245.
15. Crumb WJ Jr, Brown AM. Terfenadine blockade of a potassium current in human atrial myocytes. Circulation. 1993;88(suppl 1):I-230. Abstract.
16. Berul CI, Sweeten TL, Vetter VL, Morad M. Nonsedating antihistamines block potassium channels. J Am Coll Cardiol. 1994:182A. Abstract.
17. + current by dofetilide. Circ Res. 1993;72:75-83.
18. Salata JJ, Wasserstrom JA. Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes. Circ Res. 1988;62:324-337.
19. Lynch JJ Jr, Wallace AA, Stupienski RF III, Baskin EP, Bear CM, Appleby SD, Salata JJ, Jurkiewicz NK, Sanguinetti MC, Stein RB, et al. Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706-000 [MK-499]. J Pharmacol Exp Ther. 1994;269:541-554.
20. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195-215.
21. Hume JR, Leblanc N. A whole-cell patch clamp technique which minimizes cell dialysis. Mol Cell Biochem. 1988;80:49-57.
22. Wallace AA, Stupienski RF, Brookes LM, Selnick HG, Claremon DA, Lynch JJ. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J Cardiovasc Pharmacol. 1991;18: 687-695.
23. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686-690.
24. k and screens membrane surface charge in cardiac cells. Am J Physiol. 1990;259:H1881-1889.
25. Balser JR, Bennett PB, Roden DM. Time-dependent outward current in guinea pig ventricular myocytes: gating kinetics of the delayed rectifier. J Gen Physiol. 1990;96:835-863.
26. Gintant GA. Two components of delayed rectifier current in canine ventricular myocytes. Biophys J. 1993;64:A239. Abstract.
27. K, by flecainide and E-4031 in cat ventricular myocytes. Circulation. 1990;82:289-293.
28. + current similar to Kv1.5 cloned channel currents. Circ Res. 1993;73:1061-1076.
29. + channel current. Circ Res. 1993;73:210-216.
30. Snyders DJ, Knoth KM, Roberds SL, Tamkun MM. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol. 1992;41:322-330.
31. Lang DG, Wang CM, Wenger TL. Terfenadine alters action potentials in isolated canine Purkinje fibers more than acrivastine. J Cardiovasc Pharmacol. 1993;22:438-442.
32. Sorkin EM, Heel RC. Terfenadine. a review of its pharmaco-dynamic properties and therapeutic efficacy. Drugs. 1985;29:34-56.
33. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. Br Med J. 1989;298:325.
34. Honig PK, Zamani K, Woosley RL, Conner DP, Cantilena LR. Erythromycin changes terfenadine pharmacokinetics and electrocardiographic pharmacodynamics. Clin Pharmacol Ther. 1992; 51:156. Abstract.
35. Surawicz B. Electrophysiologic substrate of torsades de pointes: dispersion of repolarization or early after depolarization. J Am Coll Cardiol. 1989;14:172-184.
36. Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS. Astemizole: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1984;28:38-61.
37. Ozaki T, Uematsu T, Nagashima S, Nishimoto M, Nakashima M. Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: a comparative study with dobutamine. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:478-487.
38. Buchanan LV, Kabell G, Turcotte UM, Brunden MN, Gibson JK. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. J Cardiovasc Pharmacol. 1992;19: 256-263.
39. + current acting as pure class III antiarrhythmic agents. J Cardiovasc Pharmacol. 1992;20(suppl 2):S106-S113.
40. Bluth JD, Lappi MD, Billman GE. Effect of terfenadine on cardiac electrical properties and susceptibility to arrhythmias in animals with healed myocardial infarction. FASEB J. 1994;8:A77. Abstract.
41. Garteiz DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung. 1982;32:1185-1190.
42. Leeson GA, Chan KY, Knapp WC, Biedenbach SA, Wright GJ, Okerholm RA. Metabolic disposition of terfenadine in laboratory animals. Arzneimittelforschung. 1982;32:1173-1178.
43. Safety of terfenadine and astemizole. Med Lett Drugs Ther. 1992; 34:9-10.
44. 1-receptor antagonists astemizole and terfenadine: comparison to chlorpheniramine and pyrilamine. Circulation. 1994;90:I-146. Abstract.
45. Levi R, Rubin LE, Gross SS. Histamine in cardiovascular function and dysfunction: recent developments. In: Uvnas B, ed. Histamine and Histamine Antagonists: Handbook of Experimental Pharmacology, Volume 97. Berlin, FRG: Springer-Verlag; 1991:347-383.
46. Cameron JS, Gaide MS, Goad PL, Altman CB, Cuevas J, Myerburg RJ, Bassett AL. Enhanced adverse electrophysiologic effects of histamine after myocardial infarction in guinea pigs. J Pharmacol Exp Ther. 1985;232:480-484.
47. Wolff AA, Levi R. Histamine and cardiac arrhythmias. Circ Res. 1986;58:1-16.
48. Yazawa K, Abiko Y. Modulation by histamine of the delayed outward potassium current in guinea pig ventricular myocytes. Br J Pharmacol. 1993;109:142-147.
49. Backx PH, Marban E. Background potassium current active during the plateau of the action potential in guinea pig ventricular myocytes. Circ Res. 1993;72:890-900.
50. Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PKS. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Circ Res. 1991;68: 77-84.